Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.

Julio Rosenstock,Ahmed A Kolkailah,Darren K McGuire,Mark A Espeland,Michaela Mattheus,Egon Pfarr,Søren S Lund,Nikolaus Marx

Diabetes, obesity & metabolism（2023）

引用 4|浏览4

暂无评分

摘要

Across the severity spectrum, linagliptin substantially reduced the hypoglycaemic burden versus glimepiride in patients with relatively early T2D at increased cardiovascular risk. This article is protected by copyright. All rights reserved.

查看译文

关键词

DPP-4 inhibitor,glimepiride,hypoglycaemia,linagliptin,recurrent events,type 2 diabetes mellitus

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要